Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05188729 · ClinicalTrials.gov registry record · Phase 2
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
A Phase 2 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT05188729: Completed Phase 2 study, sponsored by Verrica Pharmaceuticals.
NCT05188729 is a Phase 2 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05188729, a Phase 2 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC). The study is expected to enroll approximately 86 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).
Primary Outcome
Part 1: Percentage of subjects that discontinued the study due to adverse event
Interventions
- DRUG Part 1: VP-315 3 Day Dosing/Week
- DRUG Part 2: VP-315 3 Day Dosing/Week - Loading Dose
- DRUG Part 2: VP-315 3 Day Dosing/Week - No Loading Dose
- DRUG Part 2: VP-315 2 Day Dosing/Week - Split Dose
- DRUG Part 2: VP-315 3 Day Dosing/Week - Split Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 2 |
What the finished NCT05188729 record still lists
NCT05188729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 5 interventions - of which Part 1: VP-315 3 Day Dosing/Week is the first listed.
NCT05188729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05188729 about?
NCT05188729 is a clinical study titled "Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma". This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell ca...
What is the current status of trial NCT05188729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2022-02-01. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05188729?
The interventions under investigation include: Part 1: VP-315 3 Day Dosing/Week (DRUG), Part 2: VP-315 3 Day Dosing/Week - Loading Dose (DRUG), Part 2: VP-315 3 Day Dosing/Week - No Loading Dose (DRUG), Part 2: VP-315 2 Day Dosing/Week - Split Dose (DRUG), Part 2: VP-315 3 Day Dosing/Week - Split Dose (DRUG).
Who is sponsoring clinical trial NCT05188729?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05188729's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI